IL-33/ST2信号通路在aGVHD中的作用及间充质干细胞干预的研究进展  

Research Progress on the Role of aGVHD and Its Mesenchymal Stem Cells Intervention in IL-33/ST2 Signaling Pathway

作　　者：申江艳 王洪波[1] 江明[1] 

机构地区：[1]新疆医科大学第一附属医院血液病一科,新疆 乌鲁木齐

出　　处：《临床医学进展》2024年第2期4604-4611,共8页Advances in Clinical Medicine

摘　　要：急性移植物抗宿主病(acute Graft versus Host Disease, aGVHD)是异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)后出现的严重并发症及死亡原因之一。aGVHD的发生十分复杂,许多机制尚未阐明。白细胞介素-33 (Interleukin 33, IL-33)及其受体白细胞介素1受体相关蛋白(Interleukin-1 receptor like-1,IL-1RL1,也称ST2)组成的信号通路除了参与感染性炎性疾病,自身免疫性疾病,变态反应性疾病,心血管疾病外,还参与aGVHD的发生。本文就IL-33及其受体ST2在免疫及aGVHD中的作用的研究进展进行综述,并对文献报道的aGVHD、间充质干细胞(mesenchymal stem cells, MSCs)及IL-33/ST2信号通路之间的相互作用进行梳理分析,期望为临床移植医学领域治疗aGVHD提供依据和方法。Acute graft-versus-host disease (aGVHD) is one of the serious complications and causes of death af-ter allogeneic hematopoietic stem cell transplantation (allo-HSCT). The occurrence of aGVHD is com-plex and many mechanisms have not been elucidated. The signaling pathway composed of interleu-kin 33 (IL-33) and its receptor interleukin-1 receptor like-1 protein (IL-1RL1, also known as ST2) participates in the development of aGVHD, in addition to infectious inflammatory diseases, auto-immune diseases, allergic diseases, and cardiovascular diseases. This article reviews the research progress on the role of IL-33 and its receptor ST2 in immunity and aGVHD, and analyzes the effects of mesenchymal stem cells (MSCs) on the IL-33/ST2 signaling pathway reported in literature for the treatment of aGVHD. The aim is to provide a basis and method for the clinical treatment of aGVHD in the field of transplantation medicine.

关 键 词：白细胞介素-33 ST2 AGVHD 间充质干细胞 

分 类 号：R54[医药卫生—心血管疾病]